Mumbai, 22nd October 2015: Piramal Enterprises’ Pharma Solutions division, a global leader in contract development and manufacturing (CDMO), each year participates at CPhI Worldwide. This is a convention that brings together the global pharmaceutical community to meet and identify business opportunities.
At the annual CPhI Pharma Awards this year, Piramal Pharma Solutions (PPS) took center-stage, with Vivek Sharma, CEO-Pharma Solutions, Piramal Enterprises receiving CPhI’s ‘CEO of the Year Award’ for 2015. This award was given by Pharmaceutical Executive Editor-in-Chief, William Looney, at a ceremony in Madrid, Spain, on Wednesday, Oct 14, 2015. The CPhI Pharma Awards recognise life sciences firms that turn inspiration into innovation, and celebrate thinkers and creators that are breaking new ground in formulation, process development, packaging, technology, and more.
Vivek Sharma, CEO-Pharma Solutions, Piramal Enterprises said, “I receive this award on behalf of my team and everyone at Piramal. It has been a pleasure working with my highly motivated colleagues that come to work every day with the goal of delivering medicines on time and of the highest quality. I am greatly humbled, and thank our customers for having given us an opportunity to serve them. This week has been a memorable one for us as we also won the API Supplier of the year, 2015”.
Under Vivek Sharma’s leadership, PPS has established itself as the partner of choice for both large pharma and biotech firms, by focusing on the pillars of customer centricity, quality, and innovation. These initiatives have led Piramal to be voted amongst the global top 10% contract manufacturing organizations (CMO) for both 2014 and 2015, in key categories such has quality and reliability. Piramal’s leadership in antibody drug conjugates (ADCs) has been widely recognised, with Piramal Pharma Solutions receiving the ‘Best Contract Provider for ADC’, at the World ADC Awards, 2014. Timely investments in rapidly growing segments such as ADCs, steriles, manufacturing and hormonals have also fuelled its success story.
Vivek added, “Although I do not have a healthcare background, I enjoy getting involved into the details. I bring my experience of over 20 years in operations and finance to drive efficiency, yet I learn from everyone around me. My role is to make my team successful, and we have worked hard at bringing in talent who are global experts in their respective areas. It has been a great start – we hope to build on this, and continue to deliver value to our stakeholders and our clients.”
-ENDS-
About Piramal Enterprises Limited
Piramal Enterprises Limited (PEL) is one of India’s large diversified companies, with a presence in Healthcare, Healthcare Information Management and Financial Services. PEL’s consolidated revenues were over $ 830 million in FY2015, with approx. 70% of revenues from outside India.
In healthcare, PEL is one of the leading players globally in CRAMS (custom research and manufacturing services) as well as in the critical care segment of inhalation and injectable anaesthetics. It also has a strong presence in the OTC segment in India. The Molecular Imaging Division was formed in 2012 with presence in Europe and USA.
PEL’s healthcare information management business, Decision Resources Group, is amongst the top 20 US market research organizations which provide information services to the healthcare industry.
In financial services, PEL, through its Piramal Fund Management Division, provides comprehensive financing solutions to real estate companies. The Structured Investment Group (“SIG”) provides long term patient mezzanine growth capital to capital intensive businesses which are integral part of India’s growth story. The total funds under management under these businesses are over $ 2.5 billion. The company also has strategic alliances with top global pension funds like CPPIB Credit Investment Inc. and APG Asset Management. PEL also has long term equity investments worth over $ 700 million in Shriram Group, a leading financial conglomerate in India.
PEL is listed on the Bombay Stock Exchange and the National Stock Exchange in India.
For media enquiries, please contact:
Akansha Pradhan
Corporate Communications,
Piramal Group
Tel: +91 22 3351 4082
akansha.pradhan@piramal.com
For Investors:
Hitesh Dhaddha,
Investor Relations Team,
Piramal Enterprises Limited
Tel: +91 (0) 22 6151 3430
investor.relations@piramal.com
Help employers find you! Check out all the jobs and post your resume.
